Compare Chubb Ltd (CB) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Cytokinetics Inc — how do they compare? Chubb Ltd trades at $347.09 (market cap $134.37B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Chubb Ltd is far larger — about 12.5× Cytokinetics Inc's market cap, and Chubb Ltd pays a 1.17% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CB | CYTK | |
|---|---|---|
Market Cap | $134.37B | $10.78B |
Sector | Financials | Technology |
52-Week High | $363.50 | $87.26 |
52-Week Low | $268.20 | $33.23 |
Enterprise Value | $155.22B | $10.88B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $350.31, down 1.05% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $7.26 beating estimates, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Recent news highlights leadership appointments and positive earnings coverage.
The outlook is positive, supported by consistent earnings beats, a 52.38% analyst buy rating, and a consensus price target of $366.83. Risks include macroeconomic sensitivity and competitive pressures in insurance. The stock presents a value opportunity with a P/E of 12.41 and robust cash flow trends.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
